A biotech startup developing T-cell and NK-cell therapies derived from low-immunogenicity iPS cells. It aims to provide new treatments for solid tumors and autoimmune diseases, contributing to the treatment of previously difficult-to-treat intractable diseases.
Shinobi Therapeutics（Shinobi、本社：米国カリフォルニア州サンフランシスコ、日本法人：京都府京都市）は51百万ドルのシリーズAファイナンスを完了いたしました。このラウンドには、EQT Life Sciences、Eight ...
2023年２月14日 サイアス株式会社 サイアス株式会社が三角株式交換により米国サイアス・インクを親会社とする組織再編を実施 サイアス株式会社（京都市左京区、代表取締役 等泰道、五ノ坪良輔） は、米国...
2022年1２月28日 サイアス株式会社 サイアス、約9.5 億円の AMED 委託事業に採択 iPS 細胞由来キラーT細胞療法の世界に先駆けた治験実施を目指す サイアス株式会社（京都市左京区、代表取締役 等泰道・...
2022年12月20日 サイアス株式会社 国立大学法人京都大学iPS細胞研究所 公益財団法人京都大学iPS細胞研究財団 同種iPS細胞由来CAR-NK細胞の治験薬製造に係る共同研究契約及びデータ・特許の独占的な実施...
2022年2月28日 各 位 サイアス株式会社 サイアス、Eight Roads Ventures Japan及びF-Prime Capital Partnersを新規投資家とし、総額21.3億円の資金調達完了、米国展開へ サイアス株式会社（京都府京都市...
Luxana Biotech is a preclinical antisense oligonucleotide (ASO) development company based on proprietary nucleic acids with unique cross-linking structures. We have created the LuxiAP™ ASO drug discovery platform for the central nervous system and ophthalmic fields. The company has collaborative research agreements with multiple pharmaceutical companies and maintains its own ASO pipeline. We are seeking to expand partnership opportunities not only for collaborative research with pharmaceutical companies but also for joint development utilizing our proprietary pipeline.
We are developing generative AI to support decision-making for healthcare professionals and the general public. Specifically, Cubec functions as a learning support tool that answers questions arising in physicians’ daily practice, and it generates revenue by providing pharmaceutical companies with high-precision data on physician needs. We are planning a phased business rollout, with the ultimate goal of implementing as a Software as a Medical Device (SaMD) that supports physicians’ clinical decision-making.
A startup providing the “mui Smart Living” platform for smart homes. It supports corporate digital transformation with user-friendly UI/UX and compliance with standard specifications, contributing to enhanced customer experiences in the energy and housing sectors.
HOIST is developing anti-cancer products with novel mechanism-of-action utilizing the MA-T® system. Further, we are pursuing epitranscriptomics drug discovery via a novel target, ALKBH. In addition, we run a drug discovery support business for our clients creating patient derived cells (PDC) / patient derived xenografts (PDX). In pharmaceutical development, HOIST aims to utilize partnerships with pharmaceutical companies (via licensing-out, joint drug discovery etc.). In the drug discovery support business, we tailor PDC/PDX solutions to individual needs of our clients, and contribute to higher success rate of product development.